Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pro-Inflammatory Cytokines Predict Relapse-Free Survival after One Month of Interferon-α but Not Observation in Intermediate Risk Melanoma Patients.

PloS one - 1 Jan 2015

Tarhini Ahmad A, Lin Yan, Zahoor Haris, Shuai Yongli, Butterfield Lisa H, Ringquist Steven, Gogas Helen, Sander Cindy, Lee Sandra, Agarwala Sanjiv S, Kirwood John M

Abstract excerpt

BACKGROUND: E1697 was a phase III trial of adjuvant interferon (IFN)-α2b for one month (Arm B) versus observation (Arm A) in patients with resected melanoma at intermediate risk. We evaluated the levels of candidate serum cytokines, the HLA genotype, polymorphisms of CTLA4 and FOXP3 genes and the development of autoantibodies for their association with relapse free survival (RFS) in Arm A and Arm B among 268...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CTLA-4 Antigen
Share to Cytokines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease-Free Survival

Share to Forkhead Transcription Factors

Share to HLA Antigens

Share to Interferon-alpha

Share to Melanoma

Share to Skin Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 26192408
DOI: 10.1371/journal.pone.0132745
PMCID: PMC4508028

Genes

CTLA4
FOXP3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pro-Inflammatory Cytokines Predict Relapse-Free Survival after One Month of Interferon-α but Not Observation in Intermediate Risk Melanoma Patients.PMID 26192408Read ↗

Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trial.Semantic proximity Read ↗

Immunomodulatory effects of high-dose and low-dose interferon alpha2b in patients with high-risk resected melanoma: the E2690 laboratory corollary of intergroup adjuvant trial E1690.Semantic proximity Read ↗

Genetic associations of the interleukin locus at 1q32.1 with clinical outcomes of cutaneous melanoma.Semantic proximity Read ↗

A multi-factorial genetic model for prognostic assessment of high risk melanoma patients receiving adjuvant interferon.Semantic proximity Read ↗

Evaluation of serum osteopontin level and gene polymorphism as biomarkers: analyses from the Nordic Adjuvant Interferon alpha Melanoma trial.Semantic proximity Read ↗

IL-10Rα expression is post-transcriptionally regulated by miR-15a, miR-185, and miR-211 in melanomaSemantic proximity Read ↗

Cytokine genotype polymorphisms in breast carcinoma: associations of TGF-beta1 with relapse.Semantic proximity Read ↗

IL28B polymorphism cannot predict response to interferon alpha treatment in patients with melanoma.Semantic proximity Read ↗

Cytokine gene single nucleotide polymorphisms and susceptibility to and prognosis in cutaneous malignant melanoma.Semantic proximity Read ↗

Presence of the human leukocyte antigen class II gene DRB1*1101 predicts interferon gamma levels and disease recurrence in melanoma patients.Semantic proximity Read ↗

Adoptive TIL transfer in the adjuvant setting for melanoma: long-term patient survival.Semantic proximity Read ↗

CXCL10 reduces melanoma proliferation and invasiveness in vitro and in vivoSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.